High circulating osteoprotegerin levels are associated with non-zero blood groups

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Nagy, Elod Erno ^a,b   Varga Fekete, Timea ^a   Puskas, Attila ^a   Kelemen, Piroska ^a   Brassai, Zoltan ^a   Szekeres Csiki, Katalin ^c,d   Gombos, Timea ^d   Csanyi, Maria Csilla ^d   Harsfalvi, Jolan ^d  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Central Laboratory   (Romania)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

AB0 blood groups; Atherosclerosis; Critical ischemia; Diabetes; Endothelial dysfunction; Hypertension; Osteoprotegerin; Peripheral arterial disease; Von Willebrand factor

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; COLLAGEN BINDING PROTEIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOPROTEGERIN; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; BLOOD GROUP ABO SYSTEM;

ADULT; ANALYSIS OF VARIANCE; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL LIMB ISCHEMIA; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; BLOOD; COMPARATIVE STUDY; DUPLEX DOPPLER ULTRASONOGRAPHY; INCIDENCE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHENOTYPE; RISK FACTOR; ROMANIA; SEVERITY OF ILLNESS INDEX;

ABO BLOOD-GROUP SYSTEM; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; PHENOTYPE; RISK FACTORS; ROMANIA; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84991706072     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0287-2     Document Type: Article

References (38)

1. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005;5:5-14.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509-26.
3. Garrison RJ, Havlik RJ, Harris RB, Feinleib M, Kannel WB, Padgett SJ. ABO blood group and cardiovacular disease: the Framingham study. Atherosclerosis. 1976;25:311-8.
4. Sonneveld MA, Cheng JM, Oemrawsingh RM, de Maat MP, Kardys I, Garcia-Garcia HM, van Geuns RJ, Regar E, Serruys PW, Boersma E, Akkerhuis KM, Leebeek FW. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study. Thromb Haemost. 2015;113:577-84.
5. Hosbond SE, Poulsen TS, Diederichsen ACP, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012;46:203-11.
6. Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015;72:307-26.
7. Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta. 2015;438:401-14.
8. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005;204:714-23.
9. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5:1956-62.
10. Niu Y, Zhang W, Yang Z, Li X, Wen J, Wang S, Zhang H, Wang X, Zhou H, Fang W, Qin L, Su Q. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord. 2015;15:86.
11. Liumbruno GM, Franchini M. Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus. 2013;11:491-9.
12. Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. Thromb Haemost. 2014;112:1103-9.
13. Franchini M, Lippi G. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer. BMC Med. 2015;13:7.
14. Sousa NC, Anicchino-Bizzacchi JM, Locatelli MF, Castro V, Barjas-Castro ML. The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica. 2007;92:236-9.
15. Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res. 2006;21:438-45.
16. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100:3002-7.
17. Yasuhara R, Miyamoto Y, Takami M, Imamura T, Potempa J, Yoshimura K, Kamijo R. Lysine-specific gingipain promotes lipopolysaccharide-and activevitamin D3-induced osteoclast differentiation by degrading osteoprotegerin. Biochem J. 2009;419:159-66.
18. Chan BY, Buckley KA, Durham BH, Gallagher JA, Fraser WD. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem. 2003;49:2083-5.
19. Perez de Ciriza C, Lawrie A, Varo N. Influence of pre-analytical and analytical factors on osteoprotegerin measurements. Clin Biochem. 2014;47:1279-85.
20. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem. 1982;28:1356-8.
21. Kingsbury KJ. Relation of ABO blood-groups to atherosclerosis. Lancet. 1971;1:199-203.
22. Ali Z, Ellington AA, Mosley Jr TH, Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis. 2009;206:575-80.
23. O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, Leahy AL, Kelly CJ, Agha A, Thompson CJ, O'Gorman DJ, Fitzgerald P, Smith D. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010;126:e423-7.
24. Ye Z, Ali Z, Klee GG, Mosley Jr TH, Kullo IJ. Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. Am J Hypertens. 2013;26:495-502.
25. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005; 182:175-80.
26. Hosbond SE, Diederichsen ACP, Saaby L, Rasmussen LM, Lambrechtsen J, Munkholm H, Sand NPR, Gerke O, Poulsen TS, Mickley H. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? Atherosclerosis. 2014;236:230-6.
27. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006;154:75-81.
28. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine. 2008;44:168-71.
29. Akinci B, Demir T, Celtik A, Baris M, Yener S, Ozcan MA, Yuksel F, Secil M, Yesil S. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract. 2008;82:172-8.
30. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, Martinez-Salgado C. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest. 2012;42:548-56.
31. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-33.
32. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Hoilund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011;10:76.
33. Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, Passuti N, Lambert G, Goueffic Y, Heymann D. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine. 2012;58:300-6.
34. Vinholt PJ, Overgaard M, Diederichsen AC, Mickley H, Poulsen TS, Sand NP, Nybo M, Rasmussen LM. An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma. Thromb Res. 2013;131:396-400.
35. Rutten B, Maseri A, Cianflone D, Laricchia A, Cristell N, Durante A, Spartera M, Ancona F, Limite L, Hu D, Li H, Uren N, de Groot P, Mannucci P, Roest M. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study. Eur Heart J Acute Cardiovasc Care. 2015;4:64-74.
36. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-9.
37. Dentali F, Sironi AP, Ageno W, Crestani S, Franchini M. ABO blood group and vascular disease: an update. Semin Thromb Hemost. 2014;40:49-59.
38. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111:3042-9.